Clinical trials: Connective Tissue Disorders
- Condition Connective Tissue Disorders
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Acne Vulgaris
Sebacia Postmarket Study of Real-World Use
Postmarket study of Sebacia Microparticles treatment during adoption into clinical use for patients with mild to moderate inflammatory acne vulgaris.
- Trial name
- NCT03818555
- Testing
- Sebacia Microparticles Treatment
- Where
- 6 sites in United States
- Volunteers
- 125 people
- Sponsor
- Sebacia, Inc.
Osteoarthritis, Hip, Arthritis
A Clinical Investigation of the M2a-Magnum™ Hip System
The purpose of this prospective clinical data collection is to document the performance and clinical outcomes of the M2a-Magnum™ Hip System
- Conditions
- Osteoarthritis, Hip, Arthritis, Rheumatoid Arthritis, Joint Disease
- Trial name
- NCT00698347
- Testing
- M2a-Magnum™ Hip System
- Volunteers
- 249 people
- Sponsor
- Biomet Orthopedics, LLC
Cradle Cap, Infantile Seborrheic Dermatitis
Promiseb Topical Cream for Cradle Cap
The purpose of this study is to evaluate the efficacy and safety of Promiseb Topical Cream in cradle cap.
- Trial name
- NCT01214434
- Testing
- Promiseb Topical Cream, Bland emollient
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Promius Pharma, LLC
Impetigo
EU PV for Retapamulin-Prescribing
Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the European Union (EU), retapamulin is approved for the treatment of impetigo and…
- Trial name
- NCT01153828
- Testing
- Retapamulin, Co-prescription of retapamulin and topical mupirocin, Co-prescription of retapamulin and topical fusidic acid
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Acne Vulgaris
A Treatment for Severe Inflammatory Acne Subjects
Demonstrate that a daily treatment regimen of adapalene 0.3%/benzoyl peroxide 2.5% gel + oral Doxycycline 200 mg is effective and safe in severe inflammatory acne with 3 or fewer nodules or cysts (non-nodulocystic) during a…
- Trial name
- NCT02899000
- Testing
- Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel, Oral doxycycline hyclate
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- Galderma R&D
Crohn Disease, Ulcerative Colitis
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
National, prospective, multicentre observational study designed for eligible patients treated with Inflectra. Its objectives are to describe under real conditions of use, the profile of patients treated with Inflectra and the…
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- ReFLECT (NCT02925338)
- Testing
- QOL questionaire
- Where
- 67 sites in France
- Volunteers
- 1,431 people
- Sponsor
- Pfizer
Tinea Pedis
Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox Topical Suspension 0.77% for the Treatment of Tinea Pedis
The objectives of this study were to demonstrate comparable safety and efficacy of Ciclopirox Olamine Topical Suspension (Test Product) and Ciclopirox Topical Suspension 0.77% (Reference Product) in the treatment of subjects with…
- Trial name
- NCT00804193
- Testing
- Ciclopirox Olamine Topical Suspension, Ciclopirox Topical Suspension 0.77%-Reference Product
- Volunteers
- 553 people
- Sponsor
- Padagis LLC
Melanoma
Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
This is an expanded access program (EAP) for participants who have progressed after prior systemic therapy including ipilimumab, and V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor or mitogen-activated protein…
- Trial name
- NCT02083484
- Testing
- Pembrolizumab
- Sponsor
- Merck Sharp & Dohme LLC
Acne Vulgaris
A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
Enrollment of subjects with mild to moderate facial acne vulgaris. Co-Primary efficacy endpoints included: Absolute change from Baseline to Week 12 in the inflammatory lesion counts on the face Absolute change from Baseline to…
- Trial name
- NCT03292640
- Testing
- DFD-03 (0.1% tazarotene) Lotion
- Where
- United States
- Volunteers
- 547 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa, Junctional
CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa
Epidermolysis bullosa (EB) is a group of inherited disorders characterized by fragility of the skin and mucous membranes within the basement membrane zone.
- Trial name
- MATHBULL (NCT06007235)
- Testing
- CACIPLIQ20
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement
Immunologic Diseases, Autoimmune Diseases
Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
The purpose of this study is to determine whether LJP 394 (abetimus sodium) is safe and effective in delaying and reducing renal flares in patients with lupus nephritis.
- Conditions
- Immunologic Diseases, Autoimmune Diseases, Systemic Lupus Erythematosus, Lupus Nephritis
- Trial name
- NCT00035308
- Testing
- Abetimus sodium (LJP 394)
- Where
- 82 sites in United States, Austria and 8 more
- Volunteers
- 330 people
- Sponsor
- La Jolla Pharmaceutical Company
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Skin Infections, Bacterial
Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo
The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.
- Trial name
- NCT00133874
- Testing
- SB-275833 ointment, 1%
- Where
- 69 sites in Canada, Costa Rica and 8 more
- Volunteers
- 520 people
- Sponsor
- GlaxoSmithKline
Leptomeningeal Metastasis, Leptomeningeal Disease
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
The FORESEE Study is a multi-center, prospective clinical trial enrolling patients with Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM).
- Conditions
- Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer
- Trial name
- FORESEE (NCT05414123)
- Testing
- CNSide
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Biocept, Inc.
Mucopolysaccharidosis II
A Study of JR-141 in Patients With Mucopolysaccharidosis II (BR21)
A Phase II open-label, randomized, parallel group, 2 sites (Brazil), designed to evaluate the safety and efficacy of 3 doses of study drug for the treatment of the MPS II.
- Trial name
- NCT03359213
- Testing
- JR-141
- Where
- 2 sites in Brazil
- Volunteers
- 18 people
- Sponsor
- JCR Pharmaceuticals Co., Ltd.
Acne Vulgaris
Skin Acceptance and Efficacy Assessment of a Topical Product in Acne Treatment When Compared to a Placebo.
In this study the topical use of cream with live probiotic bacteria was evaluated for its efficacy in reducing acne symptoms and its effect on the skin microbiota on patients with acne vulgaris.
- Trial name
- NCT04216160
- Testing
- ACN cream (YUN)
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- YUN NV
Hidradenitis Suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- RECHARGE-2 (NCT06840392)
- Testing
- Remibrutinib Dose A, Remibrutinib Dose B
- Where
- 129 sites in United States, Argentina and 17 more
- Volunteers
- 565 people
- Sponsor
- Novartis Pharmaceuticals
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Alopecia Areata
PF-06651600 for the Treatment of Alopecia Areata
This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss.
- Trial name
- ALLEGRO-2b/3 (NCT03732807)
- Testing
- PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2
- Where
- 155 sites in United States, Argentina and 16 more
- Volunteers
- 718 people
- Sponsor
- Pfizer
Dystrophic Epidermolysis Bullosa
A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial
This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 1/2 clinical trial(ALLO-ASC-EB-101) for 24 months.
- Trial name
- NCT03183934
- Testing
- ALLO-ASC-DFU
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Anterogen Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.